肺水腫治療市場按藥物類別、類型、給藥途徑、通路和地區分類

肺水腫治療市場預計在 2026 年達到 37.52 億美元，預計到 2033 年將達到 46.9 億美元，2026 年至 2033 年的複合年成長率為 3.2%。

由於越來越多的人患有心臟、呼吸系統和生活方式相關的健康問題，全球治療肺水腫的藥物市場正在迅速成長。肺水腫是指肺部積水的疾病，通常由心臟衰竭、感染疾病或創傷引起，因此及時就醫至關重要。

市面上有多種治療方法，包括利尿劑、血管擴張劑、ACE抑制劑、鴉片類藥物和正性肌力藥物等藥物，以及氧氣療法、人工呼吸器和肺部復健等非藥物治療方法。人們對早期診斷的意識提升，加上醫療基礎設施的改善，正在推動對有效治療方法的需求。

儘管仍有許多挑戰，例如治療費用高昂以及低收入地區醫療資源有限，但新藥研發、個人化醫療和遠端醫療管理解決方案等領域蘊藏著巨大的機會。在新藥研發和全球醫療保健成本不斷上漲的推動下，肺水腫治療市場預計將繼續快速成長，從而改善患者預後並塑造呼吸系統疾病治療的未來。

市場動態

由於心血管和呼吸系統疾病的盛行率不斷上升以及人口老化，肺水腫治療市場持續穩定成長。人們對早期診斷和早期療育重要性的認知不斷提高，推動了藥物和非藥物療法需求的成長。利尿劑、血管擴張劑、血管張力素轉換酶抑制劑、鴉片類藥物和強心藥等藥物療法仍是治療的基礎，而氧氣療法、人工呼吸器和肺部復健等支持性療法也日益普及。

藥物研發的進步、醫療基礎設施的改善以及遠端醫療在遠端患者監護的應用，都推動了市場成長。此外，對個人化醫療和標靶治療日益成長的關注，也為創新創造了機會。

然而，挑戰依然存在，包括高昂的費用、低收入社區難以獲得治療以及侵入性手術帶來的風險。監管障礙和大規模臨床試驗的需求也減緩了新治療方法的推廣應用。

儘管存在這些障礙，但在擴展數位健康解決方案、開發更安全的藥物類別以及利用人工智慧驅動的診斷技術進行早期檢測等領域仍然存在機會。

本次調查的主要特點

• 本報告對肺水腫治療市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）內的市場規模（十億美元）和復合年成長率（%）。
• 它還重點介紹了各個細分市場的潛在商機，並解釋了該市場具有吸引力的投資提案矩陣。
• 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 該報告根據以下參數對肺水腫治療市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
• 本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
• 這份肺水腫治療藥物市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員將能夠透過用於分析肺水腫治療藥物市場的各種策略矩陣輕鬆做出決策。

目錄

第1章 研究目標與前提條件

• 調查目的
• 先決條件
• 簡稱

第2章 市場範圍

• 報告概述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章 市場動態、監理及趨勢分析

• 市場動態
• 促進要素
• 抑制因素
• 市場
• 法規環境
• 產業趨勢
• 併購
• 新系統實施和核准

4. 2026-2033年全球肺水腫治療藥物市場（依藥物類別分類）

• 利尿劑
• 鴉片類鎮痛藥
• 血管擴張劑
• 心臟興奮劑
• 其他

5. 2026-2033年全球肺水腫治療市場（依類型分類）

• 心源性肺水腫
• 非心源性肺水腫

6. 2026-2033年全球肺水腫治療藥物市場（依給藥途徑分類）

• 口服
• 靜脈注射

7. 2026-2033年全球肺水腫治療藥物市場（依通路分類）

• 醫院藥房
• 零售藥房
• 網路藥房

8. 2026-2033年全球肺水腫治療市場（按地區分類）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 中東和非洲
  • 南非
  • 海灣合作理事會國家
  • 其他中東和非洲地區

第9章 競爭情勢

• 公司簡介
  • Novartis International AG
  • Cytokinetics Inc.
  • Amgen Inc.
  • AstraZeneca plc.
  • Celularity Inc
  • United Therapeutics Corporation

第10章 分析師建議

• 機會
• 分析師觀點
• Coherent Opportunity Map

第11章調查方法

• 參考
• 調查方法

Pulmonary Edema Therapeutics Market is estimated to be valued at USD 3.752 Bn in 2026 and is expected to reach USD 4.690 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.2% from 2026 to 2033.

The global market for pulmonary edema treatments is growing rapidly. This is due to increasingly individuals are getting heart disease, respiratory problems, and health problems related to their lifestyle. Pulmonary edema, which is when fluid builds up in the lungs, is often caused by heart failure, infections, or trauma. This makes it extremely essential to get help right away.

There are many different types of treatments available on the market. These include drugs like diuretics, vasodilators, ACE inhibitors, opioids, and inotropes, as well as non-drug treatments like oxygen therapy, mechanical ventilation, and pulmonary rehabilitation. Rising awareness about early diagnosis, along with improvements in healthcare infrastructure, is driving up the need for effective treatments.

Even though, there are problems like high treatment costs and limited access in low-income areas, there are chances to create new drug classes, personalized medicine, and telemedicine-based management solutions. The pulmonary edema therapeutics market is expected to keep growing quickly driven by new drug development and more funds being spent on healthcare around the world. This will lead to better patient outcomes and shape the future of respiratory care.

Market Dynamics

The pulmonary edema therapeutics market is experiencing steady expansion, propelled by the rising prevalence of cardiovascular diseases, respiratory disorders, and aging populations. Increased awareness of early diagnosis and intervention has led to rise in demand for both pharmacological and non-pharmacological treatments. Pharmacological therapies such as diuretics, vasodilators, ACE inhibitors, opioids, and inotropes remain the cornerstone of treatment, while supportive care options like oxygen therapy, mechanical ventilation, and pulmonary rehabilitation are becoming popular.

Advancements in drug development, improved healthcare infrastructure, and the integration of telemedicine for remote patient monitoring are all contributing to the growth of the market. Additionally, the growing focus on personalized medicine and targeted therapies is opening opportunity for innovation.

However, the market faces challenges such as high treatment costs, limited access in low-income regions, and risks associated with invasive procedures. Regulatory hurdles and the need for extensive clinical trials also slow down the introduction of novel therapies.

Despite these barriers, opportunities lie in expanding digital health solutions, developing safer drug classes, and leveraging AI-driven diagnostics for early detection.

Key Features of the Study

• This report provides in-depth analysis of the pulmonary edema therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the pulmonary edema therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis International AG, Cytokinetics Inc., Amgen Inc., AstraZeneca plc., Celularity Inc., and United Therapeutics Corporation.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The pulmonary edema therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the pulmonary edema therapeutics market.

Market Segmentation

• By Drug Class
  • Diuretics
  • Opioid Analgesics
  • Vasodilators
  • Inotropes
  • Others
• By Type
  • Cardiogenic Pulmonary Edema
  • Non-cardiogenic Pulmonary Edema
• By Route of Administration
  • Oral
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • South Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Competitive landscape
  • Novartis International AG
  • Cytokinetics Inc.
  • Amgen Inc.
  • AstraZeneca plc.
  • Celularity Inc.
  • United Therapeutics Corporation

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Market
• Regulatory Scenario
• Industry Trend
• Merger and Acquisitions
• New System Launches/Approvals

4. Global Pulmonary Edema Therapeutics Market, By Drug Class, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Diuretics
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Opioid Analgesics
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Vasodilators
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Inotropes
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

5. Global Pulmonary Edema Therapeutics Market, By Type, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Cardiogenic Pulmonary Edema
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Non-cardiogenic Pulmonary Edema
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

6. Global Pulmonary Edema Therapeutics Market, By Route of Administration, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

7. Global Pulmonary Edema Therapeutics Market, By Distribution Channel, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, 2026-2033, (US$ Billion)

8. Global Pulmonary Edema Therapeutics Market , By Region, 2026-2033 (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
• North America
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • U.S.
    • Canada
• Europe
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • U.K.
    • Germany
    • France
    • Russia
    • Rest of Europe
• Asia Pacific
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Regional Trends
  • Market Size and Forecast, By Drug Class, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Type, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (US$ Billion)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Billion)
  • Market Share Analysis, By Country, 2026 and 2033 (%)
    • South Africa
    • GCC Countries
    • Rest of the Middle East and Africa

9. Competitive Landscape

• Company Profiles
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • Cytokinetics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • AstraZeneca plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • Celularity Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates
  • United Therapeutics Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments/Updates

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Research Methodology

• References
• Research Methodology
• About us and Sales Contact